Humacyte (NASDAQ:HUMA) Trading Up 3.4%

Humacyte, Inc. (NASDAQ:HUMA) shares were up 3.4% during mid-day trading on Wednesday . The stock traded as high as $5.42 and last traded at $5.41. Approximately 287,785 shares traded hands during trading, a decline of 87% from the average daily volume of 2,184,317 shares. The stock had previously closed at $5.23.

Analyst Ratings Changes

Several equities research analysts have issued reports on HUMA shares. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 target price on shares of Humacyte in a research note on Tuesday, July 2nd. BTIG Research lifted their target price on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $8.60.

Humacyte Stock Performance

The firm’s 50-day moving average price is $6.91 and its two-hundred day moving average price is $5.57. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market cap of $627.57 million, a price-to-earnings ratio of -5.23 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, analysts expect that Humacyte, Inc. will post -1.09 EPS for the current fiscal year.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the sale, the director now owns 4,306,464 shares in the company, valued at $28,896,373.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 23.10% of the company’s stock.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares in the last quarter. Millennium Management LLC lifted its position in shares of Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in shares of Humacyte by 15.4% during the second quarter. Private Advisor Group LLC now owns 366,600 shares of the company’s stock worth $1,760,000 after purchasing an additional 48,976 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.